Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices

被引：0
|
作者：
Hou, Jing-Zhou
Blanc, Simon
Maglinte, Gregory A.
Vasudevan, Anupama
Rui, Anna
Gart, Mike
Pham, Hoa
Aton, Lindsay
Wang, Brandon
Choksi, Rushir J.
机构：
[1] Univ Pittsburgh Med Ctr UPMC, Pittsburgh, PA USA
[2] Integra Connect PrecisionQ, W Palm Beach, FL USA
[3] BeiGene, San Mateo, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19020
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Michael
    Hoa Pham
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir
    [J]. BLOOD, 2023, 142
  • [2] Treatment Patterns and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated With Bruton's Tyrosine Kinase Inhibitors (BTKis) in US Community Setting
    Mitul, Gandhi
    Sudeep, Karve
    Bhavini, Srivastava
    Ding, He
    Diala, Harb
    Olga, Ryan
    Juliet, Ndukum
    Ari, Marcus
    Ira, Zackon
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S56 - S56
  • [3] Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL)
    Krackeler, Margaret
    Chee, Bryant
    Orchanian, Arthur K.
    Law, Lisa Y.
    Lopez, Alfredo R.
    Buchanan, Susan
    Maglinte, Gregory A.
    Liu, Raymond
    Zhu, Zheng
    Sakoda, Lori C.
    Tavakoli, Jahan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Real-world risk of bleeding events in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with BTKi
    Moslehi, Javid J.
    Wahlstrom, Svea K.
    Teschemaker, Anna
    Mackey, Rachel H.
    DeVincenzo, Diana
    Carabuena, Leslie A.
    Thompson, Samantha L.
    Gordon, Brittaney
    Rosenthal, Ning A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients
    Lin, Kevin H.
    Huynh, Lynn
    Yang, Xiaoqin
    Zanardo, Enrico
    Lema, Neema
    Matay, Lisa
    Balasubramanian, Sobana
    Liborski, Daria
    McDonough, Mikaela
    Foreman, Jillian
    Farooqui, Mohammed Z. H.
    De Nigris, Enrico
    Gandra, Shravanthi R.
    Sarpong, Eric M.
    Duh, Mei Sheng
    Brown, Jennifer R.
    Davids, Matthew Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] REAL-WORLD TREATMENT PATTERNS AND CARDIOVASCULAR DISEASE (CVD) BURDEN IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING COVALENT BRUTON'S TYROSINE KINASE INHIBITORS (CBTKIS)
    Dingli, D.
    de Nigris, E.
    Obeng-Kusi, M.
    Leng, S.
    Lodaya, K.
    Weimer, I
    Jiao, W.
    Hyatt, H.
    Yapici, H. O.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S241 - S241
  • [7] PHYSICIAN REPORTED TREATMENT ATTRIBUTES CONSIDERED IN FIRST-LINE AND PERCEPTIONS AROUND BRUTON TYROSINE KINASE INHIBITOR (BTKI) TREATMENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) IN THE US
    Jensen, C.
    Ding, Z.
    Greenwood, T.
    Kluth, C.
    Sanderson, I
    Milloy, N.
    Mavani, H.
    Khan, W.
    Qureshi, Z. P.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S33 - S33
  • [8] Real-world understanding of the unmet need for treatment of non-covalent BTKi in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Choksi, Rushir J.
    Hou, Jing-Zhou
    Li, John
    Gart, Mike
    Vasudevan, Anupama
    Blanc, Simon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Clinical Characteristics, Treatment Patterns, and Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Refractory to Covalent Bruton's Tyrosine Kinase Inhibitor (BTKi) and Exposed to B-Cell Lymphoma 2 Inhibitor (BCL2i)
    Lin, Kevin H.
    Huynh, Lynn
    Yang, Xiaoqin
    Zanardo, Enrico
    Matay, Lisa
    Pinaire, Megan
    Liborski, Daria
    McDonough, Mikaela M.
    Foreman, Jillian
    Farooqui, Mohammed Z. H.
    De Nigris, Enrico
    Gandra, Shravanthi R.
    Sarpong, Eric M.
    Duh, Mei Sheng
    Brown, Jennifer R.
    Davids, Matthew S.
    [J]. BLOOD, 2023, 142
  • [10] Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)
    Awan, Farrukh T.
    Deshpande, Gaurav A.
    Le, Trong Kim
    Garrison, Sean
    Tiwana, Simran K.
    Priyadarshini, Masoom
    [J]. BLOOD, 2022, 140 : 7028 - 7029
12345